An Injection Without The Needle
One example of the output of our R&D is Uniflash®, a significant improvement in BTM (Buccal Transmucosal route) technology.
This new, non-invasive route of administration has efficacy comparable to an intravenous injection.
With the newly developed technology, lipophilic or amphiphilic molecules are rapidly absorbed through the buccal mucosae, and the lipophilic epithelial membrane. This highly vascular mucosa allows rapid access to the blood stream, via the sublingual and jugular veins.
This innovation allows pharmacodynamics comparable to injection, enabling direct distribution to the pulmonary and cardiac tissues, and then to the entire organism via the arterial system.
It also allows a great reduction in drug dosage to be considered, since metabolism in the liver, the famous "first pass effect," is considerably reduced.
In addition to these exciting technologies, we are constantly pushing the technology in our core: unit-doses.